Roughly one in eight American adults take a GLP-1 medication. That’s double the share from just 18 months earlier. Morgan Stanley projects the global market could reach $190 billion by 2035.
These are healthcare headlines, but they’re also logistics headlines. Nearly every one of those doses has to move through a cold-chain to reach the patient.
What GLP-1s are and how they work
GLP-1 receptor agonists mimic a hormone the gut releases after eating. They slow gastric emptying, prompt insulin release, and reduce appetite. That combination is why a drug class originally approved for type 2 diabetes became the defining weight-management therapy of the decade.
Two details matter for anyone moving this pharmaceutical. GLP-1s are peptides, so they degrade when handled outside a narrow set of conditions. They’re also a chronic therapy, refilled month after month rather than taken as a single course.
Inside the GLP-1 boom
Analysts project GLP-1 revenues will break records for any drug class in the history of drug development. Between 2018 and 2023, U.S. spending on GLP-1s rose more than 500%, from $13.7 billion to $71.7 billion. In 2025, GLP-1s accounted for roughly $132 billion, about 14% of all U.S. prescription drug spending, and nearly a third of total spending growth that year.
Indications keep widening beyond diabetes and obesity. Since 2024 the FDA has approved GLP-1s for cardiovascular risk reduction, obstructive sleep apnea, chronic kidney disease, and non-cirrhotic liver disease. Each new approval opens the door to insurance coverage, and coverage drives volume.
That growth reshaped what specialty pharmacy distribution looks like. Traditional specialty programs were built for patient populations in the tens of thousands. GLP-1 programs need infrastructure for millions, split across specialty pharmacy, retail, and manufacturer-run direct-to-patient channels.
And because it’s a chronic therapy, demand compounds instead of spiking. New patients layer on top of a growing base of existing ones, which makes capacity planning structurally harder than a seasonal surge.
GLP-1 temperature requirements: six degrees of room
Every major GLP-1 injectable requires 2–8°C storage and transport. Any time outside that range is a temperature excursion. The harder part isn’t keeping them cold enough, it’s keeping them from getting too cold. They cannot freeze, and freeze damage often leaves no visible sign. A pen that froze in transit and thawed before delivery can look exactly like one that always stayed in range. That leaves a packout defending two boundaries six degrees apart, where running warm degrades the product and running cold destroys it outright.
The cost is well documented. IQVIA estimates the biopharma industry loses roughly $35 billion a year to failures in temperature-controlled logistics. With some GLP-1 list prices above $1,000 a month, one ruined shipment is a real loss, and a temperature-related recall means answering to regulators on top of replacing the product.
How to prevent temperature excursions in transit
The reactive version of cold-chain looks like this: the data logger comes back, it shows an excursion, the pharmacy reships, someone absorbs the cost.
The proactive version makes the decisions before the box is sealed:
- Coolant optimized per shipment: Gel pack quantity should reflect the conditions a shipment will actually encounter on its route, rather than a fixed standard applied year-round. Right-sizing coolant protects the product while cutting cost and weight.
- Weather predicted, not reacted to: Major weather events should be flagged before an Rx is shipped, so a heat wave or a blizzard is accounted for rather than discovered afterward.
- Smart carrier selection: A network of pharmaceutical-qualified carriers lets you select the right one for each shipment based on performance and negotiated rates. That’s far cheaper than overnighting every order, and with the right coverage, it can still put the shipment at a patient’s doorstep in one day.
- Visibility from pickup through delivery: Monitoring across the full route allows intervention while a shipment is still recoverable.
Optimized packouts lower cold-chain costs
The instinct when stakes are this high is to overbuild: more coolant, more insulation, fastest service level, every time. That’s unnecessary cost, and it adds dimensional weight to every one of those monthly refills. With shipment optimization, real-time conditions are analyzed before each box is built, so packouts are matched to what the shipment will actually face instead of insuring against a worst case that isn’t coming. Lower cost, same protection.
GLP-1s aren’t slowing down, and the distribution side of the category is still catching up to the manufacturing side.
Rethinking how your GLP-1s ship? Let’s talk: partnerships@gripshipping.com
